Inhibition of GTPase Rac1 in endothelium by 6-mercaptopurine results in immunosuppression in nonimmune cells: New target for an old drug

Journal of Immunology

Volumn 192, Issue 9, 2014, Pages 4370-4378

  Marinković, Goran ^a   Kroon, Jeffrey ^b   Hoogenboezem, Mark ^b   Hoeben, Kees A ^a   Ruiter, Matthijs S ^a   Kurakula, Kondababu ^a   Rubio, Iker Otermin ^a   Vos, Mariska ^a   De Vries, Carlie J M ^a   Van Buul, Jaap D ^b   De Waard, Vivian ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b SANQUIN RESEARCH   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ACTIVATING TRANSCRIPTION FACTOR 2; GUANOSINE TRIPHOSPHATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; MERCAPTOPURINE; PROTEIN C JUN; RAC1 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; THIOGUANOSINE TRIPHOSPHATE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ACTIN POLYMERIZATION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ADHESION; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKOCYTE MIGRATION; MONOCYTE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

6-MERCAPTOPURINE; BLOTTING, WESTERN; CELL ADHESION; CELLS, CULTURED; COCULTURE TECHNIQUES; ENDOTHELIAL CELLS; ENZYME ACTIVATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MICROSCOPY, CONFOCAL; MICROSCOPY, ELECTRON, SCANNING; NEUTROPHILS; RAC1 GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION; TRANSCRIPTOME; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION;

EID: 84899501115     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1302527     Document Type: Article

References (47)

1. Bean, R. H. D. 1962. The treatment of chronic ulcerative colitis with 6-mercaptopurine. Med. J. Aust. 49: 592-593
2. Suarez-Almazor, M. E., C. Spooner, and E. Belseck. 2000. Azathioprine for treating rheumatoid arthritis. Cochrane Database Syst. Rev. 4: CD001461
3. Escher, J. C., J. A. Taminiau, E. E. Nieuwenhuis, H. A. Buller, and R. J. Grand. 2003. Treatment of inflammatory bowel disease in childhood: Best available evidence. Inflamm. Bowel Dis. 9: 34-58
4. Louis, E., and J. Belaiche. 2003. Optimizing treatment with thioguanine derivatives in inflammatory bowel disease. Best Pract. Res. Clin. Gastroenterol. 17: 37-46
5. McGeown, M. G., J. F. Douglas, R. A. Donaldson, C. M. Hill, J. A. Kennedy, W. G. Loughridge, and D. Middleton. 1988. Ten-year results of renal transplantation with azathioprine and prednisolone as only immunosuppression. Lancet 1: 983-985
6. Relling, M. V., M. L. Hancock, J. M. Boyett, C. H. Pui, and W. E. EVans. 1999. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood 93: 2817-2823
7. Lennard, L. 1992. The clinical pharmacology of 6-mercaptopurine. Eur. J. Clin. Pharmacol. 43: 329-339
8. Quéméneur, L., L. M. Gerland, M. Flacher, M. Ffrench, J. P. Revillard, and L. Genestier. 2003. Differential control of cell cycle, proliferation, and survival of primary T lymphocytes by purine and pyrimidine nucleotides. J. Immunol. 170: 4986-4995
9. Cuffari, C., E. G. Seidman, S. Latour, and Y. Théorêt. 1996. Quantitation of 6-Thioguanine in peripheral blood leukocyte DNA in Crohn?s disease patients on maintenance 6-mercaptopurine therapy. Can. J. Physiol. Pharmacol. 74: 580-585
10. Tiede, I., G. Fritz, S. Strand, D. Poppe, R. Dvorsky, D. Strand, H. A. Lehr, S. Wirtz, C. Becker, R. Atreya, et al. 2003. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J. Clin. Invest. 111: 1133-1145
11. Poppe, D., I. Tiede, G. Fritz, C. Becker, B. Bartsch, S. Wirtz, D. Strand, S. Tanaka, P. R. Galle, X. R. Bustelo, and M. F. Neurath. 2006. Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J. Immunol. 176: 640-651
12. Van Buul, J. D., and P. L. Hordijk. 2004. Signaling in leukocyte transendothelial migration. Arterioscler. Thromb. Vasc. Biol. 24: 824-833
13. Vestweber, D. 2002. Regulation of endothelial cell contacts during leukocyte extravasation. Curr. Opin. Cell Biol. 14: 587-593
14. Barreiro, O., M. Yanez-Mo, J. M. Serrador, M. C. Montoya, M. Vicente-Manzanares, R. Tejedor, H. Furthmayr, and F. Sanchez-Madrid. 2002. Dynamic interaction of VCAM-1 and ICAM-1 with moesin and ezrin in a novel endothelial docking structure for adherent leukocytes. J. Cell Biol. 157: 1233-1245
15. Carman, C. V., C. D. Jun, A. Salas, and T. A. Springer. 2003. Endothelial cells proactively form microvilli-like membrane projections upon intercellular adhesion molecule 1 engagement of leukocyte LFA-1. J. Immunol. 171: 6135-6144
16. Carman, C. V., and T. A. Springer. 2004. A transmigratory cup in leukocyte diapedesis both through individual vascular endothelial cells and between them. J. Cell Biol. 167: 377-388
17. Van Buul, J. D., M. J. Allingham, T. Samson, J. Meller, E. Boulter, R. Garcéa-Mata, and K. Burridge. 2007. RhoG regulates endothelial apical cup assembly downstream from ICAM1 engagement and is involved in leukocyte transendothelial migration. J. Cell Biol. 178: 1279-1293
18. Van Rijssel, J., J. Kroon, M. Hoogenboezem, F. P. Van Alphen, R. J. De Jong, E. Kostadinova, D. Geerts, P. L. Hordijk, and J. D. Van Buul. 2012. The Rhoguanine nucleotide exchange factor Trio controls leukocyte transendothelial migration by promoting docking structure formation. Mol. Biol. Cell 23: 2831-2844
19. Marinković, G., S. Hibender, M. Hoogenboezem, A. Van Broekhoven, A. F. Girigorie, N. Bleeker, A. A. Hamers, J. Stap, J. D. Van Buul, C. J. De Vries, and V. De Waard. 2013. Immunosuppressive drug azathioprine reduces aneurysm progression through inhibition of Rac1 and c-Jun-terminal-N-kinase in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 33: 2380-2388
20. Van Rijssel, J., I. Timmerman, F. P. Van Alphen, M. Hoogenboezem, O. Korchynskyi, D. Geerts, J. Geissler, K. A. Reedquist, H. W. Niessen, and J. D. Van Buul. 2013. The Rho-GEF Trio regulates a novel pro-inflammatory pathway through the transcription factor Ets2. Biol. Open 2: 569-579
21. Weston, C. R., and R. J. Davis. 2002. The JNK signal transduction pathway. Curr. Opin. Genet. Dev. 12: 14-21
22. Xu, Z., and L. A. Greene. 2006. Activation of the apoptotic JNK pathway through the Rac1-binding scaffold protein POSH. Methods Enzymol. 406: 479-489
23. Xu, Z., A. C. Maroney, P. Dobrzanski, N. V. Kukekov, and L. A. Greene. 2001. The MLK family mediates c-Jun N-terminal kinase activation in neuronal apoptosis. Mol. Cell. Biol. 21: 4713-4724
24. Fu, L., M. Balasubramanian, J. Shan, E. E. Dudenhausen, and M. S. Kilberg. 2011. Auto-activation of c-JUN gene by amino acid deprivation of hepatocellular carcinoma cells reveals a novel c-JUN-mediated signaling pathway. J. Biol. Chem. 286: 36724-36738
25. Gupta, S., D. Campbell, B. Dérijard, and R. J. Davis. 1995. Transcription factor ATF2 regulation by the JNK signal transduction pathway. Science 267: 389-393
26. Jaeschke, A., M. Karasarides, J. J. Ventura, A. Ehrhardt, C. Zhang, R. A. Flavell, K. M. Shokat, and R. J. Davis. 2006. JNK2 is a positive regulator of the cJun transcription factor. Mol. Cell 23: 899-911
27. Sabapathy, K., K. Hochedlinger, S. Y. Nam, A. Bauer, M. Karin, and E. F. Wagner. 2004. Distinct roles for JNK1 and JNK2 in regulating JNK activity and c-Jun?dependent cell proliferation. Mol. Cell 15: 713-725
28. Chaveroux, C., C. Jousse, Y. Cherasse, A. C. Maurin, L. Parry, V. Carraro, B. Derijard, A. Bruhat, and P. Fafournoux. 2009. Identification of a novel amino acid response pathway triggering ATF2 phosphorylation in mammals. Mol. Cell. Biol. 29: 6515-6526
29. Angel, P., and M. Karin. 1991. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim. Biophys. Acta 1072: 129-157
30. Hai, T., and T. Curran. 1991. Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB alters DNA binding specificity. Proc. Natl. Acad. Sci. USA 88: 3720-3724
31. Perona, R., S. Montaner, L. Saniger, I. Sánchez-Pérez, R. Bravo, and J. C. Lacal. 1997. Activation of the nuclear factor-kB by Rho, CDC42, and Rac-1 proteins. Genes Dev. 11: 463-475
32. Van Wetering, S., J. D. Van Buul, S. Quik, F. P. Mul, E. C. Anthony, J. P. ten Klooster, J. G. Collard, and P. L. Hordijk. 2002. Reactive oxygen species mediate Rac-induced loss of cell-cell adhesion in primary human endothelial cells. J. Cell Sci. 115: 1837-1846
33. Pols, T. W., P. I. Bonta, N. M. Pires, I. Otermin, M. Vos, M. R. De Vries, M. Van Eijk, J. Roelofsen, L. M. Havekes, P. H. Quax, et al. 2010. 6-Mercaptopurine inhibits atherosclerosis in apolipoprotein e.3-leiden transgenic mice through atheroprotective actions on monocytes and macrophages. Arterioscler. Thromb. Vasc. Biol. 30: 1591-1597
34. Wójciak-Stothard, B., A. Entwistle, R. Garg, and A. J. Ridley. 1998. Regulation of TNF-áinduced reorganization of the actin cytoskeleton and cell-cell junctions by Rho, Rac, and Cdc42 in human endothelial cells. J. Cell. Physiol. 176: 150-165
35. Allingham, M. J., J. D. Van Buul, and K. Burridge. 2007. ICAM-1́mediated, Srcand Pyk2-dependent vascular endothelial cadherin tyrosine phosphorylation is required for leukocyte transendothelial migration. J. Immunol. 179: 4053-4064
36. Wessel, F., M. Winderlich, M. Holm, M. Frye, R. Rivera-Galdos, M. Vockel, R. Linnepe, U. Ipe, A. Stadtmann, A. Zarbock, et al. 2014. Leukocyte extravasation and vascular permeability are each controlled in vivo by different tyrosine residues of VE-cadherin. Nat. Immunol. 15: 223-230
37. Gulbins, E., K. M. Coggeshall, B. Brenner, K. Schlottmann, O. Linderkamp, and F. Lang. 1996. Fas-induced apoptosis is mediated by activation of a Ras and Rac protein-regulated signaling pathway. J. Biol. Chem. 271: 26389-26394
38. Minden, A., A. Lin, F. X. Claret, A. Abo, and M. Karin. 1995. Selective activation of the JNK signaling cascade and c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs. Cell 81: 1147-1157
39. González-Santiago, L., Y. Suárez, N. Zarich, M. J. Muñoz-Alonso, A. Cuadrado, T. Marténez, L. Goya, A. Iradi, G. Sáez-Tormo, J. V. Maier, et al. 2006. Aplidin induces JNK-dependent apoptosis in human breast cancer cells via alteration of glutathione homeostasis, Rac1 GTPase activation, and MKP-1 phosphatase downregulation. Cell Death Differ. 13: 1968-1981
40. Arbibe, L., J. P. Mira, N. Teusch, L. Kline, M. Guha, N. Mackman, P. J. Godowski, R. J. Ulevitch, and U. G. Knaus. 2000. Toll-like receptor 2-mediated NF-kB activation requires a Rac1-dependent pathway. Nat. Immunol. 1: 533-540
41. Sulciner, D. J., K. Irani, Z. X. Yu, V. J. Ferrans, P. Goldschmidt-Clermont, and T. Finkel. 1996. rac1 regulates a cytokine-stimulated, redox-dependent pathway necessary for NF-kB activation. Mol. Cell. Biol. 16: 7115-7121
42. Gastonguay, A., T. Berg, A. D. Hauser, N. Schuld, E. Lorimer, and C. L. Williams. 2012. The role of Rac1 in the regulation of NF-kB activity, cell proliferation, and cell migration in non-small cell lung carcinoma. Cancer Biol. Ther. 13: 647-656
43. Thomas, C. W., G. M. Myhre, R. Tschumper, R. Sreekumar, D. Jelinek, D. J. McKean, J. J. Lipsky, W. J. Sandborn, and L. J. Egan. 2005. Selective inhibition of inflammatory gene expression in activated T lymphocytes: A mechanism of immune suppression by thiopurines. J. Pharmacol. Exp. Ther. 312: 537-545
44. Collins, T., M. A. Read, A. S. Neish, M. Z. Whitley, D. Thanos, and T. Maniatis. 1995. Transcriptional regulation of endothelial cell adhesion molecules: NF-kB and cytokine-inducible enhancers. FASEB J. 9: 899-909
45. Lazzerini, G., S. Del Turco, G. Basta, A. O?Loghlen, A. Zampolli, and R. D. Caterina. 2009. Prominent role of NF-kB in the induction of endothelial activation by endogenous nitric oxide inhibition. Nitric Oxide 21: 184-191
46. Roebuck, K. A., and A. Finnegan. 1999. Regulation of intercellular adhesion molecule-1 (CD54) gene expression. J. Leukoc. Biol. 66: 876-888
47. Adam, O., and U. Laufs. 2013. Rac1-mediated effects of HMG-CoA reductase inhibitors (statins) in cardiovascular disease. Antioxid. Redox Signal. 10.1089/ ars.2013.5526